(2021). IgE, blood eosinophils and FeNO are not enough for choosing a monoclonal therapy among the approved options in patients with type 2 severe asthma.
Chicago Style (17th ed.) CitationIgE, Blood Eosinophils and FeNO Are Not Enough for Choosing a Monoclonal Therapy Among the Approved Options in Patients with Type 2 Severe Asthma. 2021.
MLA (8th ed.) CitationIgE, Blood Eosinophils and FeNO Are Not Enough for Choosing a Monoclonal Therapy Among the Approved Options in Patients with Type 2 Severe Asthma. 2021.
Warning: These citations may not always be 100% accurate.